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CORRESPONDENCE
Letter to the Editor
Dear Sir,
We have read with interest the recent report by
Kaufman et al.1 of a patient who was reported
to have a visual field defect develop 13 months
following initiation of therapy with tiagabine. The
visual field defect was reported to have reversed on
discontinuation of therapy. It is important that these
results be evaluated critically because if valid, they
imply that the well-documented visual field defect
induced by vigabatrin is a class effect of compounds
that raise levels of GABA in the central nervous
system. However, we believe that there is insufficient
evidence in the Kaufman et al.1 report to support such
a conclusion for the reasons given below.
It is recognized by glaucoma specialists that a
visual field defect should be replicated at least once
prior to any consideration of initiation of therapeutic
intervention2, 3. In a large study of ocular hypertensive
patients, over 80% of new onset visual field defects
could not be replicated on the next examination4.
In addition, every major multicenter clinical trial
in glaucoma (AGIS, CIGTS, EMGT, NTG, OHTS)
has found it necessary to require replication of the
development or progression of visual field loss on
at least three consecutive visual fields in order to
distinguish true changes from long-term variability5.
The test–retest or long-term variability for automated
threshold static perimetry is well documented6–9 and
it can be quite considerable. This variability also
increases with eccentricity in the visual field7–9. For
suprathreshold static visual field screening procedures,
like those used in the Kaufman et al.1 study, the long
term variability is even greater10.
The Kaufman et al.1 study reports that a patient
receiving tiagabine developed visual field defects
consisting of missed stimuli in the outer rim of points
in the far peripheral nasal visual field of both eyes.
Compared to the initial examination, the number of
missed points increased by six in the right eye and
ten in the left eye. This is certainly well within
the expected test–retest variability for suprathreshold
static visual field screening procedures10. In addition
to variability, there are many other factors that can
produce pseudo visual field loss in the far periphery.
Apparent constriction of the visual field can also be
caused by decreased attention and fatigue11, refractive
error12 and trial lens rim artifacts13. The cooperation
and reliability of the patient can also influence
visual field test results. The present study does not
provide information pertaining to fixation losses, false
positive and false negative responses during the test.
Finally, selection of inappropriate parameters in the
Humphrey 120 point visual field screening test can add
further spurious variability to measured performance.
Specifically, the instrument presents target stimuli
at 6 dB above a threshold that can either be age
determined or determined by an estimate of central
threshold at the beginning of the test. If the latter
procedure is used, then changes in number of points
missed can be due to a fluctuation in the target
luminance used rather than a true change in patient
sensitivity
Given all of these factors, we believe that the
authors’ report of a tiagabine induced visual field
defect that reverses with drug withdrawal is not
strongly supported by the data provided. A more
thorough study did not find any visual field defects in
15 epileptic patients on tiagabine monotherapy14. A
more likely basis for the reported visual field changes
in the current study is test–retest variability, which can
occur from a variety of sources as described earlier.
Yours sincerely,
Mitchell Brigell
Pfizer Global Research & Development
Ann Arbor, MI
USA
and
Chris A. Johnson
Devers Eye Institute
Portland, OR
USA
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